# Es Follow Prostate Screening Trans Female On Estrogens

> Follow individualized prostate cancer screening for transgender females on estrogens

- Skill: `dromlakhani/es-follow-prostate-screening-trans-female-on-estrogens` (Agent Skill)
- Install (CLI): `npx skillmds@latest add dromlakhani/es-follow-prostate-screening-trans-female-on-estrogens`
- Raw SKILL.md: https://api.skillmd.com/api/skills/dromlakhani/es-follow-prostate-screening-trans-female-on-estrogens/raw
- Safety review: pending (external: skill-scanner PASS, skillspector PASS)
- Works with: Claude Code, Claude.ai, OpenAI Codex
- Category: Coding & Dev Tools
- Author: dromlakhani (https://skillmd.com/u/dromlakhani)
- Updated: 2026-09-21
- Page: https://skillmd.com/skills/dromlakhani/es-follow-prostate-screening-trans-female-on-estrogens

---


# Follow individualized prostate cancer screening for transgender females on estrogens

## STEP 1 — Gather Information
Collect demographic data (age, race/ethnicity), personal and family history of prostate cancer (especially first‑degree relatives), known genetic risk factors (BRCA1/2, HOXB13), and confirm current estrogen therapy regimen and duration.

## STEP 2 — Rule In / Rule Out
Determine if the patient is a transgender female receiving estrogen therapy; if not, this skill does not apply, otherwise proceed to risk assessment.

## STEP 3 — Classify or Stratify
Stratify personal risk into average (no first‑degree relative with prostate cancer before age 65, no known genetic mutation) versus increased (first‑degree relative diagnosed <65 years, multiple relatives, or known pathogenic mutation).

## STEP 4 — Decide
For average risk, engage in shared decision‑making about initiating PSA screening at age 50 per general population guidelines; for increased risk, consider earlier initiation (age 40‑45) and discuss frequency based on individualized risk.

## Clinical Guardrails / Mimics / Pitfalls
- Do not withhold prostate cancer screening solely because estrogen therapy lowers PSA levels; interpret PSA in context.
- Avoid screening men <40 years without high‑risk features regardless of estrogen use.
- Do not rely on estrogen‑induced prostate atrophy to rule out cancer; digital rectal exam remains relevant.
- Ensure informed consent discussing benefits, harms, and uncertainties of PSA testing.

## Concrete Clinical Example
A 55‑year‑old transgender female on oral estradiol 4 mg daily for 10 years reports her father was diagnosed with prostate cancer at age 62; she is classified as increased risk and opts to begin PSA screening at age 45 with repeat testing every 2 years after discussion of risks and benefits.

**Source:** Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons, Endocrine Society, 2017, DOI:10.1210/jc.2017-01658